# US 2009/0023164 A1 · Compositions and methods for the detection of hiv-1/hiv-2 infection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0023164 A1
- Document ID: US20090023164A1
- Status: Published application
- Kind: A1
- Application number: 11/662,370
- Filed: 2005-09-02
- Published: 2009-01-22
- Earliest claimed: 2004-09-08
- Assignees: The United States of America as Represented by the Secretary of Health and Human Services, NIH
- Inventors: Hana Golding; Surender Khurana
- Web page: https://patentgrep.com/patent/US20090023164A1

## CPC

- G01N 33/6854: {Immunoglobulins}
- C07K 14/005: from viruses
- C07K 14/161: {gag-pol, e.g. p55, p24/25, p17/18, p7, p6, p66/68, p51/52, p31/34, p32, p40}
- C07K 14/162: {env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site}
- C07K 14/163: {Regulatory proteins, e.g. tat, nef, rev, vif, vpu, vpr, vpt, vpx}
- G01N 33/56988: {HIV or HTLV}
- C12N 2740/16111: concerning HIV env
- C12N 2740/16122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2740/16222: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2740/16322: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- G01N 2333/162: env, e.g. gp160, gp110/120, gp41, V3, peptid T, DC4-Binding site
- G01N 2469/20: Detection of antibodies in sample from host which are directed against antigens from microorganisms
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

This invention relates to compositions and methods or the detection of immunodeficiency virus infection, especially immunodeficiency virus-1 (HIV-1) infection. The invention particularly concerns compositions and methods that may be used in HIV vaccine recipients whose sera may contain vaccine-generated anti-HIV-1 antibodies.

## Claims

### Claim 1

A method for detecting the presence, or measuring the concentration, of an anti-HIV-1 antibody in a biological sample of a human, wherein said method comprises conducting an immunoassay comprising the steps of:
(a) contacting said biological sample with a peptide having an epitope that is recognized by said anti-HIV-1 antibody, said contacting being under conditions sufficient to permit said anti-HIV-1 antibody if present in said sample to bind to said epitope and form a peptide-anti-HIV-1 antibody complex;
(b) contacting said formed peptide-anti-HIV-1 antibody complex with an anti-HIV-1 antibody binding molecule, said contacting being under conditions sufficient to permit said anti-HIV-1 antibody binding molecule to bind to anti-HIV-1 antibody of said formed peptide-anti-HIV-1 antibody complex and form an extended complex; and
(c) determining the presence or concentration of said anti-HIV-1 antibody in said biological sample by determining the presence or concentration of said formed extended complex;
wherein said epitope is present on a peptide having an amino acid sequence selected from the group consisting of SEQ ID NOs:1-11, 49-56, 90 and 141.

### Claim 2 (depends on 1)

The method of claim 1, wherein said immunoassay is an ELISA.

### Claim 3 (depends on 2)

The method of claim 2, wherein said ELISA comprises incubating said biological sample in the presence of a solid support, wherein said peptide is immobilized to said support, wherein said support is coated with milk, and wherein said anti-HIV-1 antibody binding molecule is selected from the group consisting of anti-human IgG+IgM-Fc, anti-human IgG-Fc, anti-human-IgG+IgM, and anti-human IgG; said anti-HIV-1 antibody binding molecule being conjugated to an enzyme.

### Claim 4 (depends on 1)

The method of claim 1, wherein said immunoassay is an immunochromatographic assay.

### Claim 5 (depends on 4)

The immunoassay of claim 4, wherein in said immunochromatographic immunoassay:
in said step (a), said biological sample is placed in contact with a first porous carrier, said first porous carrier containing said peptide, said peptide being non-immobilized and detectably labeled;
in said step (b), said formed peptide-anti-HIV-1 antibody complex is placed in contact with a second porous carrier, said second porous carrier being in communication with said first porous carrier, and containing an immobilized anti-HIV-1 antibody binding molecule; and
in said step (c), the presence or concentration of said anti-HIV antibody in said biological sample is determined by detecting the presence of said labeled peptide in said second porous carrier.

### Claim 6 (depends on 1)

The method of claim 1, wherein said epitope is present on a peptide or protein having the amino acid sequence of SEQ ID NO:2, SEQ ID NO:3 or SEQ ID NO:141.

### Claim 7 (depends on 6)

The method of claim 6, wherein said epitope is present on a peptide or protein having the amino acid sequence of SEQ ID NO:2.

### Claim 8 (depends on 6)

The method of claim 6, wherein said epitope is present on a peptide or protein having the amino acid sequence of SEQ ID NO:3 or SEQ ID NO:141.

### Claim 9 (depends on 1)

The method of claim 1, wherein said epitope is present on a peptide or protein having the amino acid sequence of SEQ ID NO:50, SEQ ID NO:51, or SEQ ID No. 55.

### Claim 10 (depends on 6)

The method of claim 6, wherein said epitope is present on a peptide or protein having the amino acid sequence of SEQ ID NO:50.

### Claim 11 (depends on 6)

The method of claim 6, wherein said epitope is present on a peptide or protein having the amino acid sequence of SEQ ID NO:51.

### Claim 12 (depends on 6)

The method of claim 6, wherein said epitope is present on a peptide or protein having the amino acid sequence of SEQ ID NO:55.

### Claim 13

A peptide or protein comprising an epitope that is recognized by an anti-HIV-1 antibody, wherein said epitope is present on a peptide having the amino acid sequence of SEQ ID NO:3, SEQ ID NO:50, or SEQ ID NO:55.

### Claim 14

A peptide or protein having the amino acid sequence of SEQ ID NO:3, SEQ ID NO:50, SEQ ID NO:55, or SEQ ID NO:141.

### Claim 15

An immunological complex comprising a peptide bound to an anti-HIV-1 antibody, wherein said anti-HIV-1 antibody is additionally bound to an anti-HIV antibody binding molecule, wherein said peptide or protein comprises an epitope that is recognized by an anti-HIV-1 antibody, said epitope being present on a peptide or protein having an amino acid sequence selected from the group consisting of SEQ ID NOs:1-11, 49-56, 90 and 141.

### Claim 16

A kit for detecting the presence, or measuring the concentration, of an anti-HIV-1 antibody in a biological sample of a human, wherein said kit comprises a hollow casing comprising a multilayer filter system, and first and second porous carriers, wherein said second porous carrier is in communication with said first porous carrier, and said first porous carrier is in communication with said multilayer filter system, a portion of which is accessible from said casing; wherein:
said first porous carrier contains a non-immobilized, labeled peptide or protein; and
said second porous carrier contains an immobilized, unlabeled antibody that binds to human IgG;
wherein said peptide or protein comprises an epitope that is present on a peptide having an amino acid sequence selected from the group consisting of SEQ ID NOs:1-11, 49-56, and 90.

### Claim 17 (depends on 16)

The kit of claim 16, wherein said epitope is present on a peptide or protein having the amino acid sequence of SEQ ID NO:2, SEQ ID NO:3 or SEQ ID NO:141.

### Claim 18 (depends on 16)

The kit of claim 16, wherein said epitope is present on a peptide or protein having the amino acid sequence of SEQ ID NO:50, SEQ ID NO:51, or SEQ ID NO:55.

### Claim 19 (depends on 16)

The kit of claim 16, wherein said epitope is present on a peptide or protein having the amino acid sequence of SEQ ID NO:90.

### Claim 20

A method for detecting the presence, or measuring the concentration, of an anti-HIV-2 antibody in a biological sample of a human, wherein said method comprises conducting an immunoassay comprising the steps of:
(a) contacting said biological sample with a peptide having an epitope that is recognized by said anti-HIV-2 antibody, said contacting being under conditions sufficient to permit said anti-HIV-2 antibody if present in said sample to bind to said epitope and form a peptide-anti-HIV-2 antibody complex;
(b) contacting said formed peptide-anti-HIV-2 antibody complex with an anti-HIV-2 antibody binding molecule, said contacting being under conditions sufficient to permit said anti-HIV-2 antibody binding molecule to bind to anti-HIV-2 antibody of said formed peptide-anti-HIV-2 antibody complex and form an extended complex; and
(c) determining the presence or concentration of said anti-HIV-2 antibody in said biological sample by determining the presence or concentration of said formed extended complex;
wherein said epitope is present on a peptide having an amino acid sequence selected from the group consisting of SEQ ID NOs:101-102.

### Claim 21

A method for detecting the presence, or measuring the concentration, of an anti-HIV-1 antibody in a biological sample of a human, wherein said method comprises conducting an immunoassay comprising the steps of:
(a) contacting said biological sample with an epitope set comprising at least one epitope that is recognized by said anti-HIV-1 antibody, wherein said epitope set consists essentially of an HIV-1 GAG p6 epitope or epitopes, an HIV-1 gp41 terminal region epitope or epitopes, or a combination of an HIV-1 GAG p6 epitope or epitopes and an HIV-1 gp41 terminal region epitope or epitopes, said contacting being under conditions sufficient to permit said anti-HIV-1 antibody if present in said sample to bind to epitopes in said epitope set and form an epitope-anti-HIV-1 antibody complex;
(b) contacting said formed epitope-anti-HIV-1 antibody complex with an anti-HIV-1 antibody binding molecule, said contacting being under conditions sufficient to permit said anti-HIV-1 antibody binding molecule to bind to anti-HIV-1 antibody of said formed epitope-anti-HIV-1 antibody complex and form an extended complex; and
(c) determining the presence or concentration of said anti-HIV-1 antibody in said biological sample by determining the presence or concentration of said formed extended complex.

### Claim 22 (depends on 21)

The method of claim 21, wherein said peptide set consists essentially of a combination of an HIV-1 GAG p6 epitope or epitopes and an HIV-1 gp41 terminal region epitope or epitopes.

### Claim 23

A method for detecting the presence, or measuring the concentration, of an anti-HIV-2 antibody in a biological sample of a human, wherein said method comprises conducting an immunoassay comprising the steps of:
(a) contacting said biological sample with an epitope set comprising at least one epitope that is recognized by said anti-HIV-2 antibody, wherein said epitope set consists essentially of an HIV-2 GAG p6 epitope or epitopes, an HIV-2 Env-gp36 epitope or epitopes, or a combination of an HIV-2 GAG p6 epitope or epitopes and an HIV-2 Env-gp36 epitope or epitopes, said contacting being under conditions sufficient to permit said anti-HIV-2 antibody if present in said sample to bind to epitopes in said epitope set and form an epitope-anti-HIV-2 antibody complex;
(b) contacting said formed epitope-anti-HIV-2 antibody complex with an anti-HIV-2 antibody binding molecule, said contacting being under conditions sufficient to permit said anti-HIV-2 antibody binding molecule to bind to anti-HIV-1 antibody of said formed epitope-anti-HIV-1 antibody complex and form an extended complex; and
(c) determining the presence or concentration of said anti-HIV-2 antibody in said biological sample by determining the presence or concentration of said formed extended complex.

### Claim 24 (depends on 23)

The method of claim 23, wherein said peptide set consists essentially of a combination of an HIV-2 GAG-p6 epitope or epitopes and an HIV-2 Env-gp36 epitope or epitopes.
